Molecular basis of skeletal muscle disorders in horses Malignant hyperthermia and Hyperkalemic periodic paralysis by Castellà Planes, Alba & Universitat Autònoma de Barcelona. Facultat de Veterinària
w
w
w
.p
o
s
te
rs
e
s
s
io
n
.c
o
m
 
www.postersession.com 
 
 
 
 
 
 
 
MOLECULAR BASIS OF SKELETAL MUSCLE DISORDERS IN HORSES 
Malignant hyperthermia and Hyperkalemic periodic paralysis 
 
Alba Castellà Planes, June 2017 
Order online at    https://www.postersession.com/order/ 
1. Objectives 
- To know at which point is the study of two of the main hereditary equine muscle 
pathologies: malignant hyperthermia (MH) and hyperkalemic periodic paralysis 
(HYPP).  
- To collect bibliography related to these disorders and their triggering agents.  
- To try to establish a link between the different characteristics of each of them.  
2. Introduction 
MH is a syndrome in which a high body temperature and muscular rigidity are the most 
characteristic clinical signs. In most cases it is caused by an autosomal dominant 
mutation in the exon 46 that codifies for de type 1 ryanodine receptor (RyR1) of the 
sarcoplasmic reticulum. This modification causes an uncontrolled release of calcium into 
the sarcoplasm and persistent muscle contraction, and it is often triggered by inhalant 
anesthesia, depolarizing muscle relaxants and, in some cases, stress. 
HYPP is a disorder that is mostly seen in Quarter Horses, Paints, Appaloosas and 
crossbreeds. It is caused by a codominant autosomal mutation in the SCN4A gene, that 
codifies for the α-subunit of the  voltage-gated sodium channel (Nav1.4) of the skeletal 
muscle. This mutation leads to a failure to the channel inactivation mechanism.  
3. Excitation-contraction coupling 
 
4. Malignant hyperthermia 
4.1. Clinical signs  
The most characteristic feature, as the pathology name  denotes, is the elevation of the 
body temperature. Other common clinical signs are muscle rigidity, rhabdomyolysis, 
fasciculations, ocular globe retraction, protrusion of the third eyelid, sweating, 
tachycardia and tachypnea. Analytical changes include lactic acidosis, elevation of the 
CK activity, hyperkalemia, high levels of Pi and myoglobinuria.  
4.2. RyR1 
The RyR1 is a calcium release channel localized in the terminal cisternae membrane of 
the sarcoplasmic reticulum and its function is essential for the muscular contraction.  
It is regulated by numerous molecules, such as ATP, caffeine, calcium (Fig. 1), 
magnesium and potassium. From all of these, calcium plays a basic regulatory role and 
increases the channel activity when its sarcoplasmic concentration is between 10 to 100 
µM.  
 
 
 
 
 
 
 
 
 
 
4.3. RyR1 HM 
The HM mutation causes a R2454G (arginine for glycine) substitution in the exon 46 
from the chromosome 10. In some cases, this change induces an exacerbated calcium 
release from the SR when the animal is exposed to halothane, succinylcholine or stress.  
To date, several abnormalities of this channel have been described: a higher sensitivity to 
caffeine, potassium and 4-chloro-m-chresol (4-CmC) (Fig. 2) and a minor inhibition 
capacity from magnesium and calcium at basal concentrations (Fig. 3). 
 
 
 
 
 
 
 
 
  
Fig 1. SR calcium release triggered with KCl, caffeine and 4-CmC in wild type RyR1 channels (des Georges et al. 2016). 
Fig 2. Calcium release from de SR triggered by increasing 
concentrations of caffeine, KCl and 4-CmC in RyR1 channels 
with and without de MH mutation (Yang et al. 2003).  
Fig 3. Inhibition of calcium release from the SR by increasing 
concentrations of calcium (Ca2+) and magnesium (Mg2+) in RyR1 
channels with and without de MH mutation (Yang et al. 2003).  
4.4. Treatment and prevention 
Treatment: immediate discontinuation of 
inhalatory anesthetic, cooling therapy with 
alcohol, cold water and cold fluid therapy 
compensated with sodium bicarbonate.  
Prevention: premedication with dantrolene 
PO 30-60 min. before anesthetic induction.  
 
4.5. Pathogenesis  
 
5. Hyperkalemic periodic paralysis  
5.1. Clinical signs  
The most common clinical signs are: facial myotonia, fasciculations in the flanks, neck 
and shoulders, sweating and, in some cases, protrusion of the third eyelid. Occasionally, 
these episodes can lead to generalized weakness, dorsal displacement of the soft palate, 
laryngeal paralysis, dyspnea and dysphagia. Some of the most typical analytical changes 
are hyperkalemia, higher total protein, and elevation of the CK and AST serum activities.  
5.2. SCN4A 
The SCN4A gene codifies for the voltage-gated sodium channel of the sarcolemma and T 
tubules, which is formed by two subunits, α and β. The α-subunit is composed of four 
domains, each of them with six transmembrane helixes, and only with this structure the 
channel could be functional. The β-subunit is responsible for the kinetics and activation 
(Fig. 4).  
In the rest state, the Nav1.4 channel remains 
closed, and it opens when a membrane potential 
reaches the threshold for contraction. The fast 
influx of sodium toward the sarcoplasm induces 
the depolarization of the sarcolemma and thus 
the beginning of the action potential in the 
myocyte. Once the membrane is depolarized, the 
sodium channels close and the potassium 
channels open to return to the polarized state.  
5.3. SCN4A HYPP 
This mutation is located in the third segment of the domain IV, near the inactivation site. 
Therefore, it causes a failure in the inactivation process of the channel. The abnormal 
influx of sodium makes the membrane to become less polarized, and thus more 
susceptible to reach the activation threshold and persistent depolarization. The 
hyperkalemia is due to the release of intracellular potassium to try to repolarize the cell.  
5.4. Treatment and prevention 
Treatment: dextrose and calcium gluconate 
as a cardioprotective, glucose and insulin, 
calcium bicarbonate or β-adrenergic 
agonists to promote the influx of potassium 
toward the intracellular fluid. In cases of 
severe dyspnea it may be necessary a 
tracheotomy.  
Prevention: low potassium diets, regular 
light exercise and/or chronic administration 
of acetazolamide or thiazides.  
5.5. Pathogenesis  
 
6. Conclusions 
- These two pathologies have been widely studied due to the fact that both of them 
have also been described in human medicine.  
- However, it has not yet been described the reason why the triggering agents, under 
the same conditions, sometimes produce a clinical episode and sometimes not.  
- The genetic testing may be necessary in some cases to allow registration, mainly of 
the Quarter Horses, to compete in some categories. The variability on the clinical 
signs, in HYPP, and in the mutation gene, in MH, highlights the need to make an 
effort to collect more information and better understand the pathogenesis.  
Fig. 4. Structure of the voltage-gated sodium channel 
(Hille and Catterall 2012). 
